Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had accrued a total of 85 patients to the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in previously untreated elderly patients with de novo poor-risk acute myelogenous leukemia (AML).

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have reached this milestone in the pivotal Phase II trial of our lead anticancer agent. We will now proceed to analyze the data and, if warranted, prepare a New Drug Application for submission to the U.S. Food and Drug Administration in 2008." He added, "We continue to plan on the release of preliminary data from this trial at the American Society of Hematology (ASH) Meeting in December."

The pivotal Phase II trial, initiated in May 2006, is evaluating Cloretazine(R) (VNP40101M) as a single agent in previously untreated AML patients over the age of 60 with de novo poor-risk AML. Patients are eligible for this trial if they are at least 60 years of age with de novo AML and have one of the following additional risk factors: (i) unfavorable cytogenetics; (ii) an ECOG performance status of 2 or greater; or (iii) a co-morbid condition that precludes them from receiving cytotoxic therapy with cytarabine and an anthracycline. Patients over the age of 70 with de novo AML who do not have favorable cytogenetics are also eligible.

The primary endpoint for this trial is the complete response rate (including complete remission (CR) and complete remission with incomplete platelet recovery (CRp)). Secondary endpoints include overall survival, disease-free survival and progression-free survival.

The trial ha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 1, 2015 Inventor of ... ana team   NuCana, a clinical ... and commercialise a portfolio of novel anti-cancer medicines, today ... as Chief Scientific Officer. Professor McGuigan was ... currently Professor of Medicinal Chemistry at the Cardiff School ...
(Date:6/30/2015)... June 30, 2015 Nortek Security & ... NTK ) and a leader in the residential ... announced it acquired mobile personal emergency response system ... Numera, Inc. Headquartered in ... implemented, mobile PERS products and cloud-based software platforms ...
(Date:6/30/2015)... 2015   Millar, Inc. , a leader in ... 2016 retirement of Craig Thummel , President/CEO and ... of service to the Company. The Company also announced ... of the Executive Management team as his successors. The ... currently Director of Sales and Marketing, as President, and ...
Breaking Medicine Technology:Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 2Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 4Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope ... in the Twin Cities on Saturday, August 1, at Spring Lake Park High School. ... provide more than $1 million worth of goods and services including free food, health ...
(Date:7/1/2015)... ... 01, 2015 , ... RowdMap Inc. is a proud participant ... “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation Task ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of private ...
(Date:7/1/2015)... OH (PRWEB) , ... July 01, 2015 , ... Franklin ... to announce Dr. Leslie King has been named Dean of the ... as Dean, Dr. King will promote and support the vision and mission of Franklin ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the ... Customers purchasing two or more Bunion Booties directly from their website, http://www.BunionBootie.com ... temporarily corrects misaligned toes and its ultra thin properties allow for protection against ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... partly to blame for the conflict in Sudan's Darfur ... U.N. Secretary-General Ban Ki-moon said in an editorial published ... in convenient military and political shorthand - an ethnic ... Ban wrote in The Washington Post. "Look to its ...
... identified individual genes that are associated with resistance to ... that may significantly enhance the ability to predict ... treatment,using a functional genomic screen. ,Resistance to ... in patients with metastatic cancer. Dr. Julian Downward from ...
... and TV presenter Charlotte Church has been preparing her playlist of ... if reports have to be believed . ,It seems ... with beau Gavin Henson, hopes that the iTunes will help her ... insider said that the Rugby star had consulted his friends, who ...
... announced that the wrappers of the diabetes drug Avandia will ... risk of congestive heart failure . ,Some of ... FDA, feel that the delay in implementation is an example ... loser. ,GlaxoSmithKline's Avandia has been in use since ...
... cancer, has been conferred the honor of CBE in the ... Leeds in UK , was first diagnosed with breast cancer ... returned to haunt her a decade later, spreading to her ... was told six years ago. ,But undaunted she ...
... (RIA Novosti) Astronauts from the Atlantis space shuttle have ... Station (ISS), a spokesperson for the US National Aeronautics ... ,During the space walk, astronauts Patrick Forrester and Steven ... (SARJ), allowing solar arrays installed earlier to rotate towards ...
Cached Medicine News:Health News:Climatic Change Cause of Dafur Conflict-UN 2Health News:New Genetic Studies Carried Out in Cancer Therapy 2Health News:42-year-old Cancer Patient Honored by British Queen for Her Fundraising Efforts 2
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Sphere Introducer...
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
... tip cannula allows atraumatic access ... for aspiration of subretinal fluids. ... beyond end of cannula. ... secure connection to a backflush ...
Medicine Products: